EU Solicits Stakeholder Views On Fairness And Structure Of EMA’s Fee System

Stakeholders finally have a chance to air their views about the European Medicine Agency’s fee and remuneration system, particularly whether it is “fair, cost-based and not unduly complex.” 

Fees
The European Commission wants stakeholders' views on the EMA's fee structure

The European Commission has launched a public consultation to gather views on the strengths and weaknesses of the European Medicines Agency’s system for collecting fees from the pharmaceutical industry for regulatory services and remunerating the regulators that perform those services.

Aimed at all relevant stakeholders, but particularly those with active experience of the fee system, such as the pharmaceutical industry,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography